Management of Adverse Effects in Tuberculosis Treatment

Introduction to Rifampicin-Induced Thrombocytopenia

Rifampicin should be permanently avoided in patients who have experienced rifampicin-induced thrombocytopenia, as rechallenging can cause severe reactions, according to the American Thoracic Society 1

The severity of thrombocytopenia can be classified into:
A complete blood count should be performed at the start of treatment, and platelet count should be repeated if symptoms suggestive of thrombocytopenia occur, with a platelet count <150,000/mm³ confirming thrombocytopenia, as suggested by the British Medical Journal 3

If thrombocytopenia is suspected, all antitubercular drugs should be suspended immediately, and the patient should be hospitalized for monitoring, considering platelet transfusion if there is active bleeding or a platelet count <10,000/mm³, and in severe cases, considering intravenous immunoglobulin (1 g/kg), as recommended by the American Thoracic Society 2
An alternative to rifampicin should be considered, with design of the alternative regimen in consultation with an infectious disease specialist 1
After platelet count normalizes, medications can be reintroduced sequentially, starting with ethambutol (least likely to cause thrombocytopenia), and then isoniazid if no reaction to ethambutol occurs, with monitoring of platelet count daily 2, 1
The reintroduction of medications should follow a gradual approach, starting with ethambutol, then adding isoniazid at a low dose (50 mg/day), increasing gradually to 300 mg/day after 2-3 days if no reaction occurs, as recommended by the Thorax journal 2

Patients with HIV are at higher risk of adverse reactions to antitubercular drugs, and should be managed in consultation with an infectious disease specialist 2
Patients with multidrug-resistant tuberculosis should be managed in consultation with an infectious disease specialist to design an effective alternative regimen 2
The use of directly observed therapy (DOT) should be considered to ensure adherence to the new regimen 2

Patients with rifampicin-induced thrombocytopenia should be educated about the need to avoid rifampicin permanently, and their records should clearly document rifampicin allergy 1
Patients should be educated about alarm symptoms (bleeding, petechiae) and monitored weekly for platelet count during the first month after reintroduction of the new regimen 2
The causative drug should be avoided permanently to prevent re-exposure and potential recurrence of thrombocytopenia 2